In the present study, our aim was to investigate the effects of 1,25-(OH)2D3/VDR treatment in SLE that are obtained by regulation the Skp2/p27 signaling pathway, with the hope of developing a novel therapeutic target for the treatment of SLE. Here, VDR is linked to systemic lupus erythematosus.